Prevalence of LMP-1 3′ Deletions in PBMCs
| Source of PBMCs . | LMP-1 DNA Positive Cases (%) . | Full-Length LMP-1* (%) . | LMP-1 3′ Deletion† (%) . | Full-Length + 3′ LMP-1 Deletion‡ (%) . |
|---|---|---|---|---|
| Healthy donors | 9/42 (21.4) | 5/9 (55.6) | 4/9 (44.4) | — |
| Patients with EBV-unrelated disorders | 9/43 (21) | 3/9 (33.3) | 5/9 (55.6)ρ | 1/9 (11.1) |
| Total of HIV-seronegative individuals | 18/85 (21.2) | 8/18 (44.4) | 9/18 (50) | 1/18 (5.6) |
| HIV-seropositive patients | 37/39 (94.9) | 17/37 (46) | 16/37 (43.2) | 4/37 (10.8)ρ |
| Total of PBMC samples analyzed | 55/124 (44.3) | 25/55 (45.4) | 25/55 (45.4) | 5/55 (9.2) |
| Source of PBMCs . | LMP-1 DNA Positive Cases (%) . | Full-Length LMP-1* (%) . | LMP-1 3′ Deletion† (%) . | Full-Length + 3′ LMP-1 Deletion‡ (%) . |
|---|---|---|---|---|
| Healthy donors | 9/42 (21.4) | 5/9 (55.6) | 4/9 (44.4) | — |
| Patients with EBV-unrelated disorders | 9/43 (21) | 3/9 (33.3) | 5/9 (55.6)ρ | 1/9 (11.1) |
| Total of HIV-seronegative individuals | 18/85 (21.2) | 8/18 (44.4) | 9/18 (50) | 1/18 (5.6) |
| HIV-seropositive patients | 37/39 (94.9) | 17/37 (46) | 16/37 (43.2) | 4/37 (10.8)ρ |
| Total of PBMC samples analyzed | 55/124 (44.3) | 25/55 (45.4) | 25/55 (45.4) | 5/55 (9.2) |
Cases with no evidence of 3′ LMP-1 deletions showing the amplification of a single LMP-1 fragment of the same size of that obtained from the DNA of the B95.8 virus strain.
Cases carrying a 30-bp deletion at the 3′ end of the LMP-1 gene.
Cases showing the concomitant amplification of a full-length and a deleted LMP-1 fragment. In 2 cases (1 in d and 1 in e), a 3′ LMP-1 deletion larger than 30 bp was observed.
ρ In one of these cases, a 3′ LMP-1 deletion larger than 30 bp was observed.